SIREN : 423982552
AMIENS INJECTION is a French company founded 26 years ago, specialized in the sector Fabrication d'autres équipements automobiles. Based in AMIENS (80080), this company of category ETI shows in 2024 a revenue of 21.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21 313 785 € | 22 181 548 € | 15 818 206 € | 11 460 583 € | 9 936 178 € | 10 496 426 € | 11 422 455 € | 12 941 624 € | 13 748 899 € |
| Net income | 32 504 € | 966 539 € | 444 212 € | 171 382 € | 56 866 € | 109 039 € | -87 309 € | 138 176 € | 445 347 € |
| EBITDA | 503 427 € | 1 476 545 € | 594 758 € | 524 880 € | -371 630 € | 158 145 € | 570 324 € | 388 871 € | 1 197 340 € |
| Net margin | 0.2% | 4.4% | 2.8% | 1.5% | 0.6% | 1.0% | -0.8% | 1.1% | 3.2% |
In 2024, AMIENS INJECTION achieves revenue of 21.3 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.6%. Slight decline of -4% vs 2023. After deducting consumption (6.6 M€), gross margin stands at 14.7 M€, i.e. a rate of 69%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 503 k€, representing 2.4% of revenue. Warning negative scissor effect: despite revenue change (-4%), EBITDA varies by -66%, reducing margin by 4.3 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 33 k€, i.e. 0.2% of revenue. This profit can be retained or distributed to shareholders.
21 313 785 €
14 748 674 €
503 427 €
228 859 €
32 504 €
2.4%
The debt ratio (= Financial debt / Equity x 100) stands at 20%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 12%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.4 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 0.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
19.603%
11.763%
0.361%
4.366
20.8%
In 2024, the debt ratio of AMIENS INJECTION (19.60) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of AMIENS INJECTION (11.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of AMIENS INJECTION (4.37) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 109.33. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 8.9x. Operating income very largely covers interest expenses: high safety margin.
109.333
8.941
In 2024, the liquidity ratio of AMIENS INJECTION (109.33) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of AMIENS INJECTION (8.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 200 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 262 days. Excellent situation: suppliers finance 62 days of the operating cycle (retail model). Inventory turnover is 24 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 245 days of revenue, i.e. 14.5 M€ to permanently finance. Over 2016-2024, WCR increased by +179%, requiring additional financing.
14 489 750 €
200 j
262 j
24 j
245 j
Indicative estimate only : the number of comparable transactions in this sector is limited (22 transactions). This range of 5 115 380€ to 11 080 083€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 22 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare AMIENS INJECTION with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication d'autres équipements automobiles
The revenue of AMIENS INJECTION in 2024 is 21.3 M€.
Yes, AMIENS INJECTION generated a net profit of 33 k€ in 2024.
The headquarters of AMIENS INJECTION is located in AMIENS (80080), in the department Somme.
The tax return of AMIENS INJECTION is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
AMIENS INJECTION operates in the sector Fabrication d'autres équipements automobiles (NAF code 29.32Z). See the 'Sector positioning' section above to compare the company with its competitors.